Skip to main content

Published locations for Checkpoint inhibition less toxic than antiangiogenic therapy in NSCLC

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Checkpoint inhibition less toxic than antiangiogenic therapy in NSCLC

User login

  • Reset your password
  • /content/checkpoint-inhibition-less-toxic-antiangiogenic-therapy-nsclc
  • /oncologypractice/article/162197/lung-cancer/checkpoint-inhibition-less-toxic-antiangiogenic-therapy
  • /hematology-oncology/article/162197/lung-cancer/checkpoint-inhibition-less-toxic-antiangiogenic